Big Money Sentiment decreased to 0.76 in 2018 Q4. It has change of 0.38, from 2018Q3’s 1.14. The ratio turned negative due to Clovis Oncology, Inc. positioning: 40 sold and 49 reduced. 23 funds took holdings and 45 increased holdings. Investors holded 53.65 million in 2018Q3 but now own 51.05 million shares or 4.86% less.
Moreover, Product Prns Ltd Limited Liability Company has 0.2% invested in Clovis Oncology, Inc. (NASDAQ:CLVS). Atwood & Palmer reported 0% of its capital in Clovis Oncology, Inc. (NASDAQ:CLVS). Rice Hall James & Assoc Ltd Liability invested 0.14% in Clovis Oncology, Inc. (NASDAQ:CLVS). Spark Investment Mngmt Limited Liability stated it has 0.55% of its capital in Clovis Oncology, Inc. (NASDAQ:CLVS). 12,317 were accumulated by Stifel Fin. State Common Retirement Fund stated it has 0% of its capital in Clovis Oncology, Inc. (NASDAQ:CLVS). Ohio-based Meeder Asset Management Inc has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Proshare Advisors Llc, Maryland-based fund reported 24,435 shs. Moreover, Citigroup Inc has 0.01% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 365,901 shs. Optimum Advsrs holds 0% or 700 shs in its capital. Putnam Invs Limited Liability Co invested in 985,503 shs or 0.05% of the stock. Sei Investments Com has 0% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 7,188 shs. Citadel Advisors Limited Liability invested in 0.01% or 611,932 shs. Royal National Bank Of Canada invested in 0% or 25,696 shs. Wells Fargo Com Mn owns 0% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 33,660 shs.

Clovis Oncology, Inc. registered $60,638 net activity with 0 insider buys and 5 selling transactions since December 4, 2018. On Tuesday, December 4 $6,029 worth of Clovis Oncology, Inc. (NASDAQ:CLVS) was sold by Rolfe Lindsey. MUEHL DANIEL W sold 188 shs worth $3,991.

Clovis Oncology, Inc. (NASDAQ:CLVS) trading at $26.54 after decline. On Mar, 19 it was reported by Barchart.com. Clovis Oncology, Inc. (NASDAQ:CLVS) has $1.40 billion MC. $42.09M less could be NASDAQ:CLVS valuation at $25.74 share price.

On May, 14 Clovis Oncology, Inc. (NASDAQ:CLVS)’s earnings report is awaited by WallStreet, as reported by Faxor. Analysts predict $-1.82 earnings per share, which is $0.28 down or 18.18 % from 2018’s $-1.54 earnings per share. -3.19 % EPS growth is what Wall Street’s predicts after $-1.88 reported EPS previous quarter.

Clovis Oncology, Inc. (NASDAQ:CLVS) Ratings Coverage

Total analysts of 8 have positions in Clovis Oncology (NASDAQ:CLVS) as follows: 4 rated it a “Buy”, 0 with “Sell” and 4 with “Hold”. The positive are 50%. Since September 25, 2018 according to StockzIntelligence Inc Clovis Oncology has 10 analyst reports. On Wednesday, February 27 the firm earned “Buy” rating by SunTrust. On Wednesday, February 27 the firm earned “Buy” rating by RBC Capital Markets. On Tuesday, February 26 the firm has “Hold” rating given by J.P. Morgan. In Wednesday, October 31 report JP Morgan downgraded it to “Neutral” rating and $16 target. On Wednesday, February 27 the firm has “Buy” rating by H.C. Wainwright given. On Wednesday, February 27 the company was maintained by Piper Jaffray. On Wednesday, October 31 the firm has “Overweight” rating given by Barclays Capital.

For more Clovis Oncology, Inc. (NASDAQ:CLVS) news announced briefly go to: Businesswire.com, Seekingalpha.com, Seekingalpha.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Clovis Oncology to Highlight Rubraca® (rucaparib) Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress – Business Wire” announced on March 16, 2019, “Piper likes OncoCyte in premarket analyst action – Seeking Alpha” on February 13, 2019, “Clovis’ rubraca tablets for women now available in Germany; shares are up 5% premarket – Seeking Alpha” with a publish date: March 04, 2019, “Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover – Nasdaq” and the last “Clovis’ (CLVS) Rubraca Gets Another US Patent, Shares Up – Nasdaq” with publication date: November 21, 2018.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.The company has $1.40 billion market cap. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.Last it reported negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.